Back to top
more

Bruker (BRKR)

(Delayed Data from NSDQ)

$63.32 USD

63.32
931,004

-0.05 (-0.08%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $63.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Instruments - Scientific

Better trading starts here.

Zacks News

Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem

The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.

Titan Medical (TMDI) Shows Promise on Strategic Developments

Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.

Varian (VAR) Set to Exhibit ProBeam Proton Therapy System

Varian's (VAR) ProBeam exhibition is in sync with its strategy to expand reach within the cancer care market.

Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon

Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.

QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease

QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.

Here's Why You Should Invest in Quest Diagnostics (DGX) Stock

Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.

LHC Group Finalizes Joint Venture Agreement With AtlantiCare

LHC Group's (LHCG) deal is in line with its current strategy of collaborating with JV partners to expand service capabilities in core markets.

Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.

Myriad Genetics' (MYGN) POLO Study Shows Positive Results

Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.

Bruker (BRKR) Up 7.5% Since Last Earnings Report: Can It Continue?

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Luminex xMAP Picked by EDP Biotech to Boost Cancer Diagnostics

Management at Luminex (LMNX) expects to see robust demand for Luminex's xMAP technology in 2019.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.

Medtronic Receives FDA Nod for SelectSite Catheter System

The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.

Masimo's Technologies to be Deployed to Boost Pediatric Care

NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.

Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.

QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients

QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.

Here's Why You Should Retain NuVasive (NUVA) Stock for Now

Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.

Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now

Investor confidence in the stock is high on Hill-Rom's (HRC) recent acquisition of Voalte.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

Varian Medical (VAR) raises revenue guidance for 2019 encourages.

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

Here's Why Momentum Investors Will Love Bruker (BRKR)

Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Bruker (BRKR) Upgraded to Buy: Here's What You Should Know

Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Looking for a Growth Stock? 3 Reasons Why Bruker (BRKR) is a Solid Choice

Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.

Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates

Bruker (BRKR) delivered earnings and revenue surprises of 16.67% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?